# Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

> **NCT01149850** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Giant Cell Glioblastoma
- Glioblastoma
- Gliosarcoma

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** temozolomide
- **OTHER:** laboratory biomarker analysis
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** microarray analysis
- **GENETIC:** DNA methylation analysis

## Key facts

- **NCT ID:** NCT01149850
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-28
- **Primary completion:** 2023-12-08
- **Final completion:** 2023-12-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01149850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01149850, "Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01149850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*